108 related articles for article (PubMed ID: 9091025)
1. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study.
Ikomi AA; Singer A
Br J Obstet Gynaecol; 1997 Mar; 104(3):385-6. PubMed ID: 9091025
[No Abstract] [Full Text] [Related]
2. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case--control study.
Lumbiganon P; Rugpao S; Phandhu-fung S; Laopaiboon M; Vudhikamraksa N; Werawatakul Y
Br J Obstet Gynaecol; 1996 Sep; 103(9):909-14. PubMed ID: 8813312
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study.
Bassaw K; Gangar K
Br J Obstet Gynaecol; 1997 Jun; 104(6):758-9. PubMed ID: 9197894
[No Abstract] [Full Text] [Related]
4. [Medical treatment of the uterine miomas in perimenopausal patients].
Olvera-Maldonado AJ; Martínez-Uribe A; Rendón-Macías ME; Sangines-Martínez A
Ginecol Obstet Mex; 2015 Jan; 83(1):41-7. PubMed ID: 26016315
[TBL] [Abstract][Full Text] [Related]
5. Unsuspected uterine carcinosarcoma (heterologous) diagnosed following conservative therapies with medroxyprogesterone acetate for presumed early-stage endometrial carcinoma.
Fujiwara H; Shibahara H; Usui R; Takamizawa S; Kosuge S; Ohwada M; Suzuki M; Sato I
Am J Reprod Immunol; 2002 Mar; 47(3):129-31. PubMed ID: 12069197
[No Abstract] [Full Text] [Related]
6. Depo medroxyprogesterone acetate (DMPA) therapy for uterine myomata prior to surgery.
Johnson N; Fletcher H; Reid M
Int J Gynaecol Obstet; 2004 May; 85(2):174-6. PubMed ID: 15099785
[No Abstract] [Full Text] [Related]
7. The myeloprotective effect of high dose medroxyprogesterone acetate (HD-MPA) in patients with carcinoma of the uterine cervix (stage II & III) treated by radiation.
Sangruchi S
J Med Assoc Thai; 1996 Sep; 79(9):604-7. PubMed ID: 8996992
[No Abstract] [Full Text] [Related]
8. Use of medroxyprogesterone acetate in the treatment of Müllerian adenosarcoma: a case report.
Hines BJ; Porges RF; Mittal K; Muggia FM; Curtin JP
Gynecol Oncol; 2002 Apr; 85(1):192-5. PubMed ID: 11925144
[TBL] [Abstract][Full Text] [Related]
9. The role of hormonal therapy in patients with uterine carcinoma.
Vinklerová P; Minář L; Felsinger M; Anton M; Ventruba P; Bednaříková M; Hausnerová J; Jandáková E; Číhalová M; Weinberger V
Ceska Gynekol; 2018; 83(4):263-270. PubMed ID: 30441956
[TBL] [Abstract][Full Text] [Related]
10. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women.
Sener AB; Seçkin NC; Ozmen S; Gökmen O; Doğu N; Ekici E
Fertil Steril; 1996 Feb; 65(2):354-7. PubMed ID: 8566261
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary lymphangioleiomyomatosis: a case report in postmenopausal woman treated with pleurodesis and progesterone (medroxyprogesterone acetate).
Zanella A; Toppan P; Nitti D; Lise M
Tumori; 1996; 82(1):96-8. PubMed ID: 8623516
[TBL] [Abstract][Full Text] [Related]
12. [Minimally invasive treatment of gynecologic cancers].
Ichikawa Y; Yoshikawa H
Gan To Kagaku Ryoho; 2001 Aug; 28(8):1090-3. PubMed ID: 11525023
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of fertility-sparing treatment of atypical polypoid adenomyoma with medroxyprogesterone acetate.
Nomura H; Sugiyama Y; Tanigawa T; Matoda M; Kanao H; Kondo E; Takeshima N
Arch Gynecol Obstet; 2016 Jan; 293(1):177-181. PubMed ID: 26209972
[TBL] [Abstract][Full Text] [Related]
14. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
15. [Recent outline of chemotherapy for uterine endometrial cancer].
Watanabe Y; Hoshiai H
Nihon Rinsho; 2004 Oct; 62 Suppl 10():346-50. PubMed ID: 15535265
[No Abstract] [Full Text] [Related]
16. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
[TBL] [Abstract][Full Text] [Related]
17. [Hormonal therapy in the treatment of endometrial adenocarcinoma].
Rob L
Ceska Gynekol; 1996 Aug; 61(4):249-50. PubMed ID: 8963496
[No Abstract] [Full Text] [Related]
18. [Hormone therapy for uterine corpus cancer--introduction].
Sugiyama T; Izutsu T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():370-4. PubMed ID: 15535270
[No Abstract] [Full Text] [Related]
19. [Pulmonary lymphangiomyomatosis: a 3-year follow-up of medroxyprogesterone acetate therapy. Apropos of a case].
Druelle S; Aubry P; Levi-Valensi P
Rev Pneumol Clin; 1995; 51(5):284-7. PubMed ID: 8745754
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer--a multicentre, open, controlled, prospectively randomised trial.
von Minckwitz G; Loibl S; Brunnert K; Kreienberg R; Melchert F; Mösch R; Neises M; Schermann J; Seufert R; Stiglmayer R; Stosiek U; Kaufmann M
Eur J Cancer; 2002 Nov; 38(17):2265-71. PubMed ID: 12441263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
